Immupharma PLC Clinical Development Collaboration with Incanthera (7735L)

TIDMIMM

RNS Number : 7735L

Immupharma PLC

31 December 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

UPDATE ON NUCANT CANCER PROGRAMME

Clinical Development Collaboration with Incanthera

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on its clinical development collaboration agreement for its Nucant cancer programme, with Incanthera Limited ("Incanthera"), a specialist oncology development company.

As announced on 7 December 2018, ImmuPharma alongside Incanthera are making good progress in finalising the 'Definitive Licence Agreement'. It has been agreed between both companies to extend the exclusivity period, which was initially granted to 31 December 2018, to 31 March 2019, in order to finalise the remaining parts of the agreement.

It is now envisaged that the 'Definitive Licence Agreement' will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 
 
  For further information please contact: 
   ImmuPharma plc (www.immupharma.com)           + 44 (0) 207 152 4080 
   Dimitri Dimitriou, Chief Executive Officer 
   Lisa Baderoon, Head of Investor Relations     + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                 +44 (0) 203 368 8974 
    Vassil Kirtchev 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes                 +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                 +44 (0) 1483 413500 
  About Incanthera Limited 
 
   Incanthera Limited was formed in 2010 as a spin-out from 
   the Institute of Cancer Therapeutics at Bradford University 
   and is targeting the treatment of cancer through a portfolio 
   of unique technologies. Having successfully commercialised 
   its lead product in 2017, it is actively acquiring technologies 
   to further enhance its portfolio of cancer therapeutics. 
   For more information, please visit: www.incanthera.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCLFFELFTLAFIT

(END) Dow Jones Newswires

December 31, 2018 02:00 ET (07:00 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024